Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome.
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2018
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms CHOP-OR
- 27 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 27 May 2015 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 07 Jan 2015 Accrual to date is 107% according to United Kingdom Clinical Research Network record.